Introduction
The epidermal growth factor receptor (EGFR) belongs to the ErbB family of transmembrane receptor tyrosine kinases (RTK) (1) . Due to increased activity and/or expression in human malignancies and its role in e.g. cell proliferation, migration and invasion, EGFR emerged as potent molecular target (2) (3) (4) .
Upon binding of ligands like EGF or Amphiregulin, EGFR dimerization results in RTK autophosphorylation and channeling of mitogenic signals predominantly via the Ras-extracellular signal-regulated kinase (ERK), Akt and c-Jun NH2-terminal kinases (JNK) pathway (1) .
Preclinical work demonstrated effectiveness of pharmacological inhibitors and antibodies against EGFR in tumor cells from head and neck, lung, colon, and others (3, (5) (6) (7) (8) (9) (10) . Cetuximab, for example, is approved for use in combination with radiotherapy of treatment-naïve patients with locally advanced head and neck squamous cell carcinomas (HNSCC) and as monotherapy for recurrent or metastatic HNSCC (11, 12). These trials showed significantly increased rates of both loco-regional control and overall survival.
Despite this clinical success, escape or efficacy-attenuating mechanisms in response to
Cetuximab treatment have been widely neglected. Recent studies suggested EGFR ubiquitination, cooperative EGFR-Src family kinase interactions, ErbB2 signaling and p53 are involved in reduced Cetuximab efficacy in colorectal or non small cell lung cancer cell lines (13) (14) (15) (16) . As our understanding of EGFR signaling in cancer is still marginal and obviously tumor type-dependent, it is of high clinical relevance to elucidate escape mechanisms of Cetuximab in HNSCC by taking into consideration how HNSCC cells grow in vivo. Our own work and work from others have shown that three-dimensional (3D) growth conditions are more physiologically relevant with regard to cell morphology, gene and protein expression patterns, protein-protein interactions and intracellular signaling as well as response to irradiation and chemotherapeutics relative to conventional 2D monolayer cell cultures (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . untreated cells. This experiment was performed once. Where indicated, protein phosphorylation data were confirmed by Western blotting.
Immunoprecipitation and sequential mass spectrometry
3D grown cells were lyzed with cell lysis buffer (Cell Signaling) supplemented with Complete protease inhibitor cocktail (Roche). Protein-G-Agarose beads (Sigma) were incubated with EGFR antibody or non-specific mouse IgG antibody over night. Protein lysates were added to the beads and incubated over night. After SDS-PAGE, gel fixation and Coomassie (Merck) staining, MS analysis was performed at the MPI-CBG MS Facility (Dresden) as published (26, 27) . Proteins were first in-gel digested with Trypsin as described in (28) and the LC-MS/MS analysis of extracted peptide mixtures was performed on an Ultimate nanoLC systems (Dionex) interfaced on-line to a LTQ Orbitrap hybrid mass spectrometer (Thermo Fisher Scientific) via a robotic nanoflow ion source TriVersa (Advion BioSciences Ltd.) as described in (28) . Acquired spectra were searched against human IPI protein databases. Spectra were matched by MASCOT software (Matrix Science, v.2.2.0) under following settings: mass tolerance was set as ±10 ppm for precursor and ±0.5 Da for fragmentation spectra; variable modifications: Propionamide (C), N-acetylation (Protein N-terminus), Oxidation (M); enzyme: trypsin; one missed cleavage allowed. The result was evaluated by Scaffold software (Proteome Software) under the following settings: minimal number of peptides was 2; minimal peptide and protein probabilities -95% and 99% respectively.
Data analysis
Means ± SD of at least three independent experiments were calculated with reference to untreated controls defined in a 1.0 scale. To test statistical significance, Student's t test was performed using Microsoft® Excel 2003. Results were considered statistically significant if a P-value of less than 0.05 was reached. Densitometry of Western blots was performed with ImageJ analysis software (http://rsbweb.nih.gov/ij).
Results

Growth conditions severely impact on EGFR phosphorylation and signaling
Research. We first characterized and compared EGFR expression and phosphorylation of three SCC cell lines in 3D lrECM versus conventional monolayer cultures versus tumor xenografts (Fig. 1A) . Intriguingly, patterns of EGFR expression and EGFR Tyrosine (Y)1068 and Y1173 as well as ERK1/2 Threonine (T)202/Y204 phosphorylation showed great similarity in FaDu and UTSCC14 cells grown in 3D lrECM and in vivo (Fig. 1B, C) . Akt T308 phosphorylation was higher in 3D than in 2D but only matched with in vivo levels in FaDu cells (Fig. 1B, C) . The extreme levels of EGFR phosphorylation in A431 cells might be causative for only small detectable differences of proteins of interest under the different growth conditions (Fig. 1B, C) . To our knowledge, this is the first comparative analysis of EGFR signaling in HNSCC cells growing in 3D, in vivo or as monolayer providing strong support for 3D lrECM based cell cultures as correlates to in vivo growth conditions.
Cytotoxicity and radiosensitizing potential of Cetuximab
The inhibitory potential of Cetuximab under serum starvation and subsequent EGF stimulation was performed. EGF exposure resulted in enhanced EGFR Y1173 and Y1068 phosphorylation in FaDu and UTSCC14 cells ( Supplementary Fig. S1 ). Next, we analyzed the effects of Cetuximab on clonogenic survival of 3D and 2D grown SCC cell lines and found great inter-cell line variances independently of 3D or 2D culture settings ( Fig. 2A, B and Supplementary Table S1 ). In contrast to monolayer cell cultures ( Fig. 2A, C) , 3D lrECM cell cultures were significantly (P < 0.01) and concentration-dependently radiosensitized by Cetuximab ( Fig. 2A, D) , while apoptosis induction was negligible in this context ( Supplementary Fig. S2 and S3 ). From these results we conclude Cetuximab efficacy alone to be independent of growth conditions in contrast to, combined Cetuximab/irradiation treatment regimes in SCC cell lines.
Phosphoproteome modifications upon Cetuximab-mediated EGFR inhibition
Next, we sought to identify the modifications of the intracellular signaling network resulting from Cetuximab treatment by using phosphoproteome-array technique. This array contains 1318 wellcharacterized phospho-specific antibodies. EGFR and ERK1/2-, Akt-and JNK-related signaling pathways were selected from the complete data set (data not shown). Only proteins with modified phosphorylation of ≤67% and ≥150% from Cetuximab-treated 3D FaDu cell cultures were listed according to pathway after normalization to untreated controls (Fig. 3A, 4A ). In general, the data showed reduced phosphorylation at kinase-stimulating sites as well as increased phosphorylation at kinase-inhibitory sites in response to Cetuximab (Fig. 3A, 4A ). Detection of total phosphotyrosine and phosphothreonine levels supported this observation ( Supplementary Fig. S4 ). For EGFR, we found reduced phosphorylation at five out of the ten examined EGFR sites, i.e. Y1068/1069 and Y1172/1173, borderline changes at four sites, and induction at EGFR Y1016 (Fig. 3A) . Selective confirmatory Western blot analysis of basal and Cetuximab-related EGFR phosphorylation patterns demonstrated ~70% reduction in EGFR phosphorylation at particular sites independent from growth conditions; however, for 3D cell culture and tumor xenograft, the reduction was significant (Fig. 3B,   C ). Moreover, inhibition of EGFR resulted in decreased phosphorylation levels of downstream mitogen-activated protein kinase (MAPK) signaling pathways including MAPK kinase (MEK; ~45% reduction in Western blot), ERK1/2 (~80% reduction in Western blot), E twenty-six-like transcription factor 1 (Elk1), MAPK-interacting kinase 1 (MNK1) and cAMP response element-binding protein (CREB) (Fig. 3) . Interestingly, changes in Growth factor receptor-bound protein 2 (Grb2), Ras and Raf were not observed. EGFR blocking also led to significant dephosphorylation of Phosphoinositide-3 kinase (PI3K) and Akt in 3D and in vivo by 80% and 70%, respectively, in contrast to 2D ( 
JNK2 depletion enhances Cetuximab-induced radiosensitization
Due to the context dependency of JNK with regard to anti-and prosurvival effects, we next investigated whether the Cetuximab-induced JNK2 hyperphosphorylation modifies Cetuximab efficacy (Fig. 4, 5A ). JNK2 targeting using siRNA or the pharmacological inhibitor SP600125 resulted in significant cytotoxicity in 3D FaDu cell cultures ( Table S3) . Similar results were obtained upon SP600125 treatment (Fig. 5C ). EGFR knockdown caused higher radiosensitization than Cetuximab alone and remained unchanged by additional Cetuximab administration (Fig. 5D ). Of note, EGFR depletion prevented Cetuximabinduced JNK2 hyperphosphorylation and JNK inhibition abrogated Cetuximab-dependent activation of c-Jun (Fig. 5D and Supplementary Fig. S6 ). In Cetuximab resistant UTSCC5 cells, supportive data were generated delineating JNK2 to be key for radiosensitization by Cetuximab ( Supplementary Fig.   S7 and Supplementary Table S3 ). These observations demonstrate a novel link between EGFR and JNK2 signaling and suggest this interaction plays a critical role in the self-attenuating process that reduces the radiosensitizing potential of Cetuximab.
JIP-4 connects EGFR to JNK2
By performing mass spectrometry on EGFR-immunoprecipitates, we identified a variety of interacting proteins (Supplementary Table S2 ). The most potent candidate found in these immunoprecipitates from Cetuximab-treated 3D FaDu cell cultures which connects EGFR to JNK signaling was JIP-4 ( Fig.   6A and Supplementary Fig. S8 ). The radiosensitization by JIP-4 depletion was superimposable to that of Cetuximab, and Cetuximab-induced JNK2 hyperphosphorylation was prevented (Fig. 6B and   Supplementary Table S3 ). An enhanced recruitment of JIP-4 to Cetuximab-inhibited EGFR was visualized by immunofluorescence staining and colocalization measurement in 3D FaDu cell cultures as compared to controls (Fig. 6C ). These data demonstrate a functional role of JNK2 in the radiation survival response of 3D lrECM grown cells and suggest JNK2 activation under Cetuximab-dependent EGFR inhibition to be transduced by interaction of EGFR with JIP-4 (Fig. 6D) .
Discussion
Understanding EGFR signaling in cancer is essential for treatment optimization and individualization.
In addition to a plethora of novel molecular biology technologies, 3D cell cultures have been postulated to better reflect in vivo growth condition and, therefore, might be highly valuable to support this endeavor. Here, we present data showing great similarity in EGFR signal transduction events between 3D lrECM HNSCC cell cultures and HNSCC tumor xenografts in contrast to monolayer cell 
cultures. Effective EGFR inhibition by Cetuximab elicited concentration-dependent cytotoxicity and radiosensitization. In our phosphoproteome analyses, we observed a strong induction of JNK2 phosphorylation potentially resulting from Cetuximab-inhibited EGFR. Suppressing bypass signaling via JIP-4 or JNK2 inhibition enhanced Cetuximab efficacy and tumor cell radiosensitivity. These findings add new facets to EGFR signaling with particular focus on resistance pathways which limit tumor cell eradication and radiosensitization.
As emphasized earlier (8, 18, (29) (30) (31) (32) (33) , growth conditions critically impact on growth factor receptor activity and downstream signaling offering a certain degree of plasticity for bypass signaling.
In cancer cells, these mechanisms may considerably contribute to radio-and chemoresistance as well as resistance to novel molecular agents. Our study presents compelling data on the resemblance of EGFR associated signaling in 3D lrECM cell cultures and corresponding tumor xenografts. Regarding the differences in EGFR phosphorylation in 3D versus 2D, the similarity in the cytotoxicity profiles of Cetuximab was unexpected. Importantly, radiosensitization of 3D SCC cell cultures corroborated with tumor sensitization of SCC tumor xenografts (7, 9) and improved locoregional control and overall survival of head and neck cancer patients treated with combined radiotherapy and Cetuximab (11, 12). A mechanistic explanation for Cetuximab-mediated radioprotection of 2D grown cells is currently lacking but should take into consideration signal transduction events, gene expression and cell cycling (20, 21, 25) . The JNK family members serve in a multifunctional, environment-driven and cell line/typedependent manner (34, 35) . Amongst many factors, X-ray radiation is a well known JNK activator (35, 36) . To prove whether JNK2 is mechanistically involved in a Cetuximab-self-attenuating reaction, While JNK2 inhibition conferred cytotoxicity and radiosensitization on its own, concomitant JNK2 knockdown plus Cetuximab acted in an additive manner. By using a Cetuximab resistant cell line, i.e. UTSCC5, we were able to confirm the importance of JNK2 for Cetuximab-mediated radiosensitization.
One possible candidate connecting EGFR and JNK2 is JIP-4, which we found by mass spectrometry of Cetuximab-EGFR immunoprecipitates. JIPs serve as scaffold proteins for interactions of different MAPK family members for distributing biochemical cues through specific signaling cascades (37, 38) . By means of colocalization studies and gene silencing, we provide evidence that JIP-4 is more intensively recruited to Cetuximab-inhibited, membranous EGFR and that JIP-4 depletion prevents Cetuximab-mediated JNK2 and c-Jun hyperphosphorylation. Moreover, single JIP- t-test; * P < 0.05, ** P < 0.01). Results show mean ± SD (n = 3; t-test). * P < 0.05, ** P < 0.01. Phosphorylation was normalized to total protein expression (mean ± SD; n = 2; t-test; * P < 0.05, ** P Phosphorylation was normalized to total protein expression (mean ± SD; n = 2; t-test; * P < 0.05, ** P < 0.01). D, Schematic of activated or deactivated proteins of the PI3K/Akt and JNK signaling pathway upon Cetuximab treatment (according to www.phosphosite.com). 
